SHILPAMED vs ZYDUSLIFE: Stock Comparison
ZYDUS LIFESCIENCES is the larger company by market capitalisation. SHILPA MEDICARE shows faster revenue growth and lower leverage, while ZYDUS LIFESCIENCES shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SHILPAMED leads 3; ZYDUSLIFE leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SHILPAMED | ZYDUSLIFE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | SHILPAMED | ZYDUSLIFE |
|---|---|---|
| Live Price | ₹860.8 | ₹1,135 |
| Day Change | 1.85% | 1.58% |
| Volume | 14.95 L | 13.58 L |
| 52-Week High | ₹1,095 | ₹1,232.1 |
| 52-Week Low | ₹259.5 | ₹835.5 |
| Distance from 52W High | -21.39% | -7.88% |
Valuation
| Metric | SHILPAMED | ZYDUSLIFE |
|---|---|---|
| Market Cap | ₹16,892 Cr | ₹1.13 L Cr |
| P/E Ratio | 56.66x | 25.26x |
| P/B Ratio | 6.5x | 4.21x |
| EPS | ₹5.16 | ₹9.42 |
| Book Value | ₹132.49 | ₹296.56 |
| Dividend Yield | 0.07% | 0.09% |
Growth
| Metric | SHILPAMED | ZYDUSLIFE |
|---|---|---|
| Revenue Growth (TTM YoY) | 31.5% | 16.2% |
| EPS Growth (TTM YoY) | 644.6% | 8.7% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | SHILPAMED | ZYDUSLIFE |
|---|---|---|
| ROE | 9.39% | 15.04% |
| ROCE | 9.1% | 12.84% |
| Net Margin | 15.82% | 18.36% |
| Operating Margin | 23.01% | 42.36% |
| Debt to Equity | 0.25x | 0.31x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | SHILPAMED | ZYDUSLIFE |
|---|---|---|
| Promoter Holding | 40.13% | 75.01% |
| FII Holding | 12.11%▲ 0.73 pp | 7.05%▲ 0.17 pp |
| DII Holding | 8.26%▲ 0.21 pp | 11.28%▲ 0.01 pp |
| Public Holding | 39.49%▼ 0.94 pp | 6.66%▼ 0.17 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SHILPA MEDICARE and ZYDUS LIFESCIENCES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.